Press Releases Press Releases Year: - Any -2019201820172016201520142013 October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries September 25, 2018 Summary ToggleMelinta Therapeutics to Present at Upcoming Investor Conferences September 24, 2018 Summary ToggleMelinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 September 21, 2018 Summary ToggleMelinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) September 18, 2018 Summary ToggleMelinta Therapeutics Names Peter Milligan as Chief Financial Officer September 06, 2018 Summary ToggleMelinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference August 29, 2018 Summary ToggleMelinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference August 07, 2018 Summary ToggleMelinta Therapeutics Reports Second Quarter 2018 Financial Results August 03, 2018 Summary ToggleMelinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -2019201820172016201520142013 October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries September 25, 2018 Summary ToggleMelinta Therapeutics to Present at Upcoming Investor Conferences September 24, 2018 Summary ToggleMelinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 September 21, 2018 Summary ToggleMelinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) September 18, 2018 Summary ToggleMelinta Therapeutics Names Peter Milligan as Chief Financial Officer September 06, 2018 Summary ToggleMelinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference August 29, 2018 Summary ToggleMelinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference August 07, 2018 Summary ToggleMelinta Therapeutics Reports Second Quarter 2018 Financial Results August 03, 2018 Summary ToggleMelinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
